The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ratio ...

NICE has recommended rucaparib as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

A wide selection of therapies are available to treat advanced prostate cancer, but the optimal treatment strategy is unknown.

Cutting-edge clinical research conducted by Florida Cancer Specialists & Research Institute, LLC (FCS) is being shared this ...

HTL0039732 (also known as NXE0039732) is Nxera’s novel oral EP4 antagonist with the potential to treat a wide range of ...

One hundred and twenty-four (84.9%) patients received olaparib, 17 (11.6%) received rucaparib, four (2.7%) received talazoparib, and one (0.7%) received niraparib. Fig 1. Clinical outcomes for ...